ClinicalTrials.gg
CompletedNCT05842941Updated Nov 18, 2026Results posted

HEALEY ALS Platform Trial - Regimen G DNL343

A Phase 2/3 interventional study of DNL343 and Matching Placebo in Amyotrophic Lateral Sclerosis, sponsored by Merit E. Cudkowicz, MD. Completed at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Merit E. Cudkowicz, MD · Phase 2/3, Interventional, and Treatment

How we know

Updated Nov 18, 2026Posted results revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
249
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Enrollment
33rd of 307
249 · median 33
Started
2023
with 11 others
Phase 2/3
18 of 440
1 open now
Registered
341st of 440
by date
Lead sponsor
9 of 440
Merit E. Cudkowicz, MD

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 33rd largest by enrollment of the 307 interventional ones that give a count, is one of 12 that started in 2023, is one of 18 in phase 2/3, and was the 341st registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.

Regimen G will evaluate the safety and efficacy of a single study drug, DNL343, in participants with ALS.

Read the detailed description

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. This trial is designed as a perpetual platform trial. This means that there is a single Master Protocol dictating the conduct of the trial. The HEALEY ALS Platform Trial Master Protocol is registered as NCT04297683. Once a participant enrolls into the Master Protocol and meets all eligibility criteria, the participant will be eligible to be randomized into any currently enrolling regimen. All participants will have an equal chance of being randomized to any currently enrolling regimen.

If a participant is randomized to Regimen G DNL343, the participant will complete a screening visit to assess additional Regimen G eligibility criteria. Once Regimen G eligibility criteria are confirmed, participants will complete a baseline assessment and be randomized in a 3:1 ratio to either active DNL343 or matching placebo.

Regimen G will enroll by invitation, as participants may not choose to enroll in Regimen G. Participants must first enroll into the Master Protocol and be eligible to participate in the Master Protocol before being able to be randomly assigned to Regimen G.

For a list of enrolling sites, please see the HEALEY ALS Platform Trial Master Protocol under NCT04297683.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • ALS
  • Placebo-Controlled
  • Double-Blind
  • Regimen Specific Appendix
  • Lou Gehrig's Disease
  • DNL343
  • Denali Therapeutics
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683).

Exclusion criteria

Exclusion Criteria:

  • The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683).

    1. Diagnosis of epilepsy or seizure within 6 months of randomization
    2. to DNL343 or any of the contained within the DNL343 drug product
    3. The concomitant use of prescription or over-the-counter (OTC) medications that are inducers of certain cytochrome P450 enzymes, substrates of certain cytochrome P450 enzymes, or substrates of certain drug transporters.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
249 participants (actual)

Study arms

  • Experimental
    DNL343

    Drug: DNL343

  • Placebo comparator
    Matching Placebo

    Drug: Matching Placebo

Interventions

  • DrugEvetifatorStudies of EvetifatorEvetifator pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    DNL343 is administered orally once daily per day for 24 weeks.

  • DrugMatching Placebo

    Matching placebo is administered orally once daily per day for 24 weeks.

06

What researchers measure

Primary outcomes

  1. Disease Progression as Assessed by the ALSFRS-R-Slope

    Change in disease severity as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) total score using a Bayesian repeated measures model that accounts for loss to follow-up due to mortality. Each of 12 questions assessing distinct functional ability is scored from 4(normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Participants with higher scores have more physical function. Note that only participants who survived to their Week 24 visit contribute to the estimate.

    Time frame: Baseline to 24 Weeks

  2. Mortality Event Rate

    The Mortality Rate, presented as mean deaths per month, was estimated from a Bayesian shared-parametric model that assumed exponentially distributed survival times. Mortality is defined as death or death equivalent. A participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row.

    Time frame: Baseline to 24 weeks

Secondary outcomes

  1. ALSFRS-R Total Score

    Change in ALSFRS-R total score over time. Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Participants with higher scores have more physical function.

    Time frame: Baseline to 24 Weeks

  2. Combined Assessment of Function and Survival (CAFS)

    Combined assessment of function and survival (CAFS) ranks participants' clinical outcomes based on survival time and change in the functional score. Each participant's outcome is compared to every other participant's outcome, assigned a score, and the summed scores are ranked. The mean rank score for each treatment group can then be calculated. A higher mean CAFS rank score indicates a better group outcome. The survival outcome is death or death-equivalent, where a participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row. The functional outcome is the ALS Functional Rating Scale-Revised (ALSFRS-R) score with a maximum total score of 48 and a minimum total score of 0. Participants with higher scores have more physical function.

    Time frame: Baseline to 24 Weeks

  3. Respiratory Function

    Change in respiratory function over time as assessed by slow vital capacity (SVC)

    Time frame: Baseline to 24 Weeks

  4. Upper Limb Muscle Strength

    Change in upper limb muscle strength over time as measured isometrically using hand-held dynamometry and grip strength, calculated as the average percent change from baseline of the following muscles/maneuvers: shoulder flexion, elbow flexion, elbow extension, wrist extension, abductor pollicis brevis contraction, abductor digiti minimi contraction, first dorsal interosseous contraction, and grip strength. Note that only those with measurable strength at baseline were included.

    Time frame: 24 weeks

  5. Number of Participants With Death or Permanent Assisted Ventilation (PAV)

    The number of participants who died or met the criterion for a death equivalent from the date of their baseline visit to the end of the Week 24 visit window (generally 175 days after baseline). The death equivalent criterion is use of permanent assisted ventilation (PAV) for more than 22 hours per day for more than 7 days in a row.

    Time frame: Baseline to 24 weeks

  6. Number of Participants Who Experience Death

    The number of participants who died from the date of their baseline visit to the end of the Week 24 visit window (generally 175 days after baseline).

    Time frame: Baseline to 24 weeks

  7. Disease Progression Biomarker

    Change in log-transformed serum neurofilament light protein (NfL) concentration from baseline to Week 24

    Time frame: Baseline to 24 weeks

07

Results

Posted Jan 28, 2026

Participant flow

Participant flow — Overall Study
MilestoneDNL343Matching Placebo
Started18663
Completed15655
Not completed308

Outcome measures

PrimaryDisease Progression as Assessed by the ALSFRS-R-Slope

Change in disease severity as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) total score using a Bayesian repeated measures model that accounts for loss to follow-up due to mortality. Each of 12 questions assessing distinct functional ability is scored from 4(normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Participants with higher scores have more physical function. Note that only participants who survived to their Week 24 visit contribute to the estimate.

Time frame:
Baseline to 24 Weeks
Reported as:
Mean · Percent change
Disease Progression as Assessed by the ALSFRS-R-Slope
Percent changeDNL343Matching Placebo
Disease Progression as Assessed by the ALSFRS-R-Slope-0.84 ± 0.075-0.87 ± 0.060
Statistical analysis
  • DNL343 vs Matching Placebo · Bayesian shared-parameter model · Disease rate ratio: 1.05 · 95% CI 0.84 to 1.31DDR \<1 imply slowing of disease progression by DNL343 relative to placebo. Note: reported "Confidence Interval" is actually a Bayesian credible interval.
SecondaryALSFRS-R Total Score

Change in ALSFRS-R total score over time. Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Participants with higher scores have more physical function.

Time frame:
Baseline to 24 Weeks
Reported as:
Least squares mean · Points
ALSFRS-R Total Score
PointsDNL343Matching Placebo
ALSFRS-R Total Score-5.87 ± 0.44-5.46 ± 0.52
Statistical analysis
  • DNL343 vs Matching Placebo · Mixed Models Analysis · p = 0.60 · Mean difference (net): -0.41 · 95% CI -1.90 to 1.09Covariates: baseline (BL) of use edaravone, riluzole, \& Relyvrio, BL log NfL, SVC and TRICALS score and interaction with visit
SecondaryCombined Assessment of Function and Survival (CAFS)

Combined assessment of function and survival (CAFS) ranks participants' clinical outcomes based on survival time and change in the functional score. Each participant's outcome is compared to every other participant's outcome, assigned a score, and the summed scores are ranked. The mean rank score for each treatment group can then be calculated. A higher mean CAFS rank score indicates a better group outcome. The survival outcome is death or death-equivalent, where a participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row. The functional outcome is the ALS Functional Rating Scale-Revised (ALSFRS-R) score with a maximum total score of 48 and a minimum total score of 0. Participants with higher scores have more physical function.

Time frame:
Baseline to 24 Weeks
Reported as:
Least squares mean · Rank
Combined Assessment of Function and Survival (CAFS)
RankDNL343Matching Placebo
Combined Assessment of Function and Survival (CAFS)152.89 ± 9.22162.05 ± 7.02
Statistical analysis
  • DNL343 vs Matching Placebo · Mixed Models Analysis · p = 0.44 · Mean difference (net): -9.16 · 95% CI -32.52 to 14.19DNL343 24-week change from baseline relative to placebo 24-week change from baseline.
SecondaryRespiratory Function

Change in respiratory function over time as assessed by slow vital capacity (SVC)

Time frame:
Baseline to 24 Weeks
Reported as:
Least squares mean · 24-week diff. of percents of normal VC
Respiratory Function
24-week diff. of percents of normal VCDNL343Matching Placebo
Respiratory Function-12.22 ± 1.46-9.68 ± 1.61
Statistical analysis
  • DNL343 vs Matching Placebo · Mixed Models Analysis · p = 0.28 · Mean difference (net): -2.55 · 95% CI -7.14 to 2.05DNL343 24-week change from baseline relative to placebo 24-week change from baseline.
SecondaryUpper Limb Muscle Strength

Change in upper limb muscle strength over time as measured isometrically using hand-held dynamometry and grip strength, calculated as the average percent change from baseline of the following muscles/maneuvers: shoulder flexion, elbow flexion, elbow extension, wrist extension, abductor pollicis brevis contraction, abductor digiti minimi contraction, first dorsal interosseous contraction, and grip strength. Note that only those with measurable strength at baseline were included.

Time frame:
24 weeks
Reported as:
Least squares mean · Percent change
Upper Limb Muscle Strength
Percent changeDNL343Matching Placebo
Upper Limb Muscle Strength-33.92 ± 2.42-38.32 ± 2.73
Statistical analysis
  • DNL343 vs Matching Placebo · Mixed Models Analysis · p = 0.26 · Mean difference (net): 4.40 · 95% CI -3.29 to 12.09DNL343 24-week change from baseline relative to placebo 24-week change from baseline.
PrimaryMortality Event Rate

The Mortality Rate, presented as mean deaths per month, was estimated from a Bayesian shared-parametric model that assumed exponentially distributed survival times. Mortality is defined as death or death equivalent. A participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row.

Time frame:
Baseline to 24 weeks
Reported as:
Mean · Events per month
Mortality Event Rate
Events per monthDNL343Matching Placebo
Mortality Event Rate0.007 ± 0.00210.007 ± 0.0020
SecondaryNumber of Participants With Death or Permanent Assisted Ventilation (PAV)

The number of participants who died or met the criterion for a death equivalent from the date of their baseline visit to the end of the Week 24 visit window (generally 175 days after baseline). The death equivalent criterion is use of permanent assisted ventilation (PAV) for more than 22 hours per day for more than 7 days in a row.

Time frame:
Baseline to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Death or Permanent Assisted Ventilation (PAV)
ParticipantsDNL343Matching Placebo
Number of Participants With Death or Permanent Assisted Ventilation (PAV)85
Statistical analysis
  • DNL343 vs Matching Placebo · Log Rank · p = 0.7628
SecondaryNumber of Participants Who Experience Death

The number of participants who died from the date of their baseline visit to the end of the Week 24 visit window (generally 175 days after baseline).

Time frame:
Baseline to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Experience Death
ParticipantsDNL343Matching Placebo
Number of Participants Who Experience Death64
Statistical analysis
  • DNL343 vs Matching Placebo · Log Rank · p = 0.8662
SecondaryDisease Progression Biomarker

Change in log-transformed serum neurofilament light protein (NfL) concentration from baseline to Week 24

Time frame:
Baseline to 24 weeks
Reported as:
Least squares mean · ng/L
Disease Progression Biomarker
ng/LDNL343Matching Placebo
Disease Progression Biomarker0.075 ± 0.022-0.006 ± 0.026
Statistical analysis
  • DNL343 vs Matching Placebo · Mixed Models Analysis · p = 0.03 · Mean difference (net): 0.081 · 95% CI 0.009 to 0.153Covariates: baseline (BL) of use edaravone, riluzole, \& Relyvrio, BL log NfL, and TRICALS score and interaction with visit

Adverse events

Collected over Up to 35 weeks after participant signed Master Protocol consent. For safety analyses, the analysis populations include all anticipated and unanticipated safety events (i.e. Deaths, Serious Adverse Events, and Other Adverse Events) due to any cause, that occurred or worsened on or after treatment initiation to either the final safety visit, the date of death, the date of last study contact, or the date of first dose of study drug during participation in the ATE period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DNL3436/186 (3.2%)28/186 (15.1%)149/186 (80.1%)
Matching Placebo3/63 (4.8%)10/63 (15.9%)43/63 (68.3%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventDNL343Matching Placebo
PneumoniaInfections and infestations4/1860/63
Respiratory failureRespiratory, thoracic and mediastinal disorders3/1861/63
ConstipationGastrointestinal disorders1/1861/63
Gastrointestinal haemorrhageGastrointestinal disorders0/1861/63
AppendicitisInfections and infestations0/1861/63
BronchitisInfections and infestations0/1861/63
Femur fractureInjury, poisoning and procedural complications0/1861/63
Limb traumatic amputationInjury, poisoning and procedural complications0/1861/63
Traumatic intracranial haemorrhageInjury, poisoning and procedural complications1/1861/63
Transverse sinus thrombosisNervous system disorders0/1861/63
Most frequent other events
Showing 10 of 19
Most frequent other events
EventDNL343Matching Placebo
FallInjury, poisoning and procedural complications73/18613/63
Muscular weaknessNervous system disorders42/1866/63
FatigueGeneral disorders41/18610/63
ConstipationGastrointestinal disorders30/1867/63
HeadacheNervous system disorders30/18610/63
DiarrhoeaGastrointestinal disorders20/1868/63
Urinary tract infectionInfections and infestations19/1860/63
NeuromyopathyNervous system disorders11/1866/63
NauseaGastrointestinal disorders17/1864/63
Muscle contractions involuntaryNervous system disorders10/1865/63

Baseline characteristics

Baseline Analysis Population includes only placebo participants from the Regimen G Efficacy Regimen Only (ERO) sample; shared placebo participants from other regimens are not included in the Baseline Analysis Population.

Age, Continuous
Age, Continuous(Years)DNL343Matching PlaceboTotal
Mean59.5 ± 11.5557.3 ± 11.9258.94 ± 11.66
Sex: Female, Male
Sex: Female, Male(Participants)DNL343Matching PlaceboTotal
Female821395
Male10450154
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DNL343Matching PlaceboTotal
American Indian or Alaska Native000
Asian516
Native Hawaiian or Other Pacific Islander000
Black or African American314
White17561236
More than one race101
Unknown or Not Reported202
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DNL343Matching PlaceboTotal
Hispanic or Latino15520
Not Hispanic or Latino16957226
Unknown or Not Reported213
ALS Diagnosis from R El Escorial Criteria
ALS Diagnosis from R El Escorial Criteria(Participants)DNL343Matching PlaceboTotal
Clinically Possible ALS20525
Clinically Probable ALS - Laboratory Supported361046
Clinically Probable ALS622688
Clinically Definite ALS682290
ALS Onset Location
ALS Onset Location(Participants)DNL343Matching PlaceboTotal
Axial101
Bulbar29635
Generalized000
Limb15556211
Multiple112
Respiratory000
Time Since Symptom Onset at Baseline
Time Since Symptom Onset at Baseline(Months)DNL343Matching PlaceboTotal
Mean19.7 ± 8.0521.0 ± 7.9120.1 ± 8.02
Delay in ALS Symptom Onset and Diagnosis
Delay in ALS Symptom Onset and Diagnosis(Months)DNL343Matching PlaceboTotal
Mean10.3 ± 6.2410.8 ± 5.6810.4 ± 6.10

11 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Healey Center for ALS at Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
09

References and documents

Publications

  • Paganoni S, Chibnik LB, Quintana M, Macklin EA, Detry MA, Vestrucci M, Paulon G, McGlothlin A, Wang J, Walk D, Elman L, Chase M, Heyd L, Harkey B, Sherman AV, Shefner J, Berry JD, Scirocco E, Giacomelli E, Yu H, Kittle G, Hall M, Ho D, Jawdat O, Ladha S, Locatelli E, Rivner M, Felice K, Katz J, Ajroud-Driss S, Fee D, Miller T, Rosow L, Quick A, Heitzman D, Foster LA, Maragakis NJ, Goutman SA, Rosenfeld J, Benatar M, Swenson A, Connors RD, Shroff S, Bedlack R, McIlduff CE, Chen IA, Fernandes JAM, Walsh A, Peltier A, Ilieva H, Diaz F, Kushlaf H, Beydoun SR, Myers B, Arcila-Londono X, Heiman-Patterson T, Elliott M, Whitesell J, Al-Lahham T, Elliott M, Olney N, Baer M, Jackson C, Young E, Caress J, Weiss MD, Kuenzler R, Nayar S, Kasarskis EJ, Simmons Z, Gibson S, Owegi MA, Goyal NA, Wymer JP, Gwathmey KG, Erickson A, Gursoy N, Alameda G, Bodkin C, Wu A, Martinez-Thompson J, Twydell PT, Andrews J, Bayat E, Rezania K, Usman U, McCluskey L, Kovvuru S, Jennings D, Garza-Meilandt A, Maciuca R, Cohen IV, Tamuly D, Eren E, Cudkowicz ME, Babu S; HEALEY ALS Platform Trial Study Group. DNL343 and Disease Progression in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Netw Open. 2026 Sep 1;9(9):e2634809. doi: 10.1001/jamanetworkopen.2026.34809. PubMed 42771346 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Oct 2024, 17 months.

Results were first posted in Jan 2026, 1 year 2 months after primary completion.

Of 22 phase 2/3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 109. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2023
First posted
May 6, 2023
StartActual
May 24, 2023
Primary completionActual
Oct 29, 2024
CompletionActual
Oct 29, 2024
Results first posted
Jan 28, 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Nov 18, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42771346 ↗
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Posted results revised
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42771346 ↗

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05842941
Lead sponsor
Merit E. Cudkowicz, MD
Collaborators
Denali Therapeutics Inc.
Responsible party
Merit E. Cudkowicz, MD (Chief, Neurology Department, Massachusetts General Hospital) — Sponsor-investigator
First posted
May 6, 2023
Start date
May 24, 2023
Primary completion
Oct 29, 2024
Completion
Oct 29, 2024
Results posted
Jan 28, 2026
Last update
Nov 18, 2026

Study contacts

Merit Cudkowicz, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evetifator

Start the discussion